Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Plans Hong Kong IPO to Raise up to $300 Million

publication date: Aug 22, 2018

Zai Lab is planning to list its shares on the Hong Kong exchange, according to unnamed sources, in a transaction that could raise up to $300 million. One year ago, the company completed a $172 million NASDAQ debut offering. Zai is following the lead of BeiGene, which raised $900 million in Hong Kong after initially listing on NASDAQ. The Zai transaction is expected to be 10% to 20% of its expanded share base; it currently has a market capitalization of $1.2 billion. More details....

Stock Symbol: (NSDQ: ZLAB) (NSDQ: BGNE)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here